Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial-Reference-Cited by-同舟云学术

Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial

Published:2022-11-25 Issue:30 Volume:41 Page:5789-5809
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statistics in Medicine

Author:

Mozgunov Pavel¹^ORCID,Jaki Thomas¹²^ORCID,Gounaris Ioannis³,Goddemeier Thomas⁴,Victor Anja⁴,Grinberg Marianna⁴⁵

Affiliation:

1. MRC Biostatistics Unit University of Cambridge Cambridge UK

2. Computational Statistics Group, University of Regensburg Regensburg Germany

3. Merck Serono Ltd., an affiliate of Merck KGaA Feltham UK

4. Biostatistics, Epidemiology & Medical Writing Merck Healthcare KGaA Darmstadt Germany

5. Marianna Grinberg, Statistical Sciences and Innovation UCB Monheim Germany

Funder

Merck KGaA

Medical Research Council Canada

NIHR

NIHR Cambridge Biomedical Research Centre

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sim.9594

Reference47 articles.

1. The Impact of Early-Phase Trial Design in the Drug Development Process

2. The future of immune checkpoint therapy

3. Competing designs for drug combination in phase I dose-finding clinical trials

4. A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies

5. BarnettHY GeorgeM SkanjiD Saint‐HilaryG JakiT MozgunovP.A comparison of model‐free Phase I dose escalation designs for dual‐agent combination therapies. arXiv preprint arXiv:2104.14923 2021.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applications of the partial-order continual reassessment method in the early development of treatment combinations;Clinical Trials;2024-03-30

2. Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges;Frontiers in Pharmacology;2023-11-23